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Abstract
A major concern in Pluripotent Stem Cell (PSC)-derived cell replacement therapy is the risk of teratoma formation from
contaminating undifferentiated cells. Removal of undifferentiated cells from differentiated cultures is an essential step
before PSC-based cell therapies can be safely deployed in a clinical setting. We report a group of novel small molecules that
are cytotoxic to PSCs. Our data indicates that these molecules are specific and potent in their activity allowing rapid
eradication of undifferentiated cells. Experiments utilizing mixed PSC and primary human neuronal and cardiomyocyte
cultures demonstrate that up to a 6-fold enrichment for specialized cells can be obtained without adversely affecting cell
viability and function. Several structural variants were synthesized to identify key functional groups and to improve
specificity and efficacy. Comparative microarray analysis and ensuing RNA knockdown studies revealed involvement of the
PERK/ATF4/DDIT3 ER stress pathway. Surprisingly, cell death following ER stress induction was associated with a
concomitant decrease in endogenous ROS levels in PSCs. Undifferentiated cells treated with these molecules preceding
transplantation fail to form teratomas in SCID mice. Furthermore, these molecules remain non-toxic and non-teratogenic to
zebrafish embryos suggesting that they may be safely used in vivo.
Citation: Richards M, Phoon CW, Goh GTW, Seng EK, Guo XM, et al. (2014) A New Class of Pluripotent Stem Cell Cytotoxic Small Molecules. PLoS ONE 9(3):
e85039. doi:10.1371/journal.pone.0085039
Editor: Ernst Wolvetang, University of Queensland, Australia
Received May 2, 2013; Accepted November 22, 2013; Published March 19, 2014
Copyright:  2014 Richards et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by the Singapore Ministry of Education Innovation Fund grant MOE IF-2008-1-043. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mark_richards@nyp.gov.sg (MR); dbscwk@nus.edu.sg (WKC)
. These authors contributed equally to this work.
Introduction
The discovery of induced Pluripotent Stem Cells (iPSCs) by
Yamanaka and co-workers [1] and improvements in ‘‘xeno-free’’
and feeder-free PSC culture systems [2] have significantly
advanced the prospects of PSC-based regenerative medicine
therapies. However, 3 major hurdles in regenerative medicine
still remain. First, the genetic instability of PSCs needs to be
resolved [3–6]. Second, scale-up protocols with the capacity to
culture PSCs to generate sufficient numbers of cells for clinical
application have to be formulated [5,7]. Third, methods to
consistently and completely eliminate teratoma-forming undiffer-
entiated PSCs that potentially contaminate clinically important
specialized derivatives need to be derived [5–6,8–12].
The third problem of tumor formation by rogue PSCs is
particularly worrying as just 100 hESCs are capable of forming
teratomas [11]. This estimate has made the complete removal of
undifferentiated PSCs for certain disease targets where billions of
specialized cells are necessary for transplantation (eg. diabetes and
heart conditions) particularly daunting. Indeed the focus for PSC-
based cell therapies has shifted somewhat to clinical trials where
the transplantation of smaller numbers of cells would be sufficient
for a cure, like in the case of eye disease such as Macular
Dystrophy where only tens of thousands of PSC-derived Retinal
Pigment Epithelial cells are required to restore sight in patients
[13].
A variety of strategies have been suggested to eliminate rogue
undifferentiated PSCs residing in a pool of differentiated cells.
These include the selective removal of undifferentiated PSCs in
the heterogeneous cell population via flow cytometry [14], the
development of cytotoxic antibodies that specifically target
undifferentiated PSCs [15,16], the separation of undifferentiated
PSCs from the differentiated cells prior to transplantation using
cell sorting methods alone or in combination with density gradient
separation [17,18], deliberate extended differentiation of PSC-
derivatives to allow residual undifferentiated PSCs to differentiate
into an undesirable cell type [19], and the creation of transgenic
PSC lines with suicide genes that can be activated at will to
selectively remove undifferentiated cells before transplantation
[9,20].
Many of these solutions are antibody-based. However, while
antibodies have high specificity they are relatively difficult and
costly to produce. Their routine use in enrichment protocols to
process large numbers of cells will also escalate the cost of clinical
application. Processing of cells for FACS or MACS is also lengthy
and time consuming and may ultimately lead to cell attrition and
loss of cell viability.
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Results
To overcome the issues associated with existing antibody-based
enrichment paradigms, we conducted a large-scale screen with the
BGO1V hESC line supported on Mouse Embryonic Fibroblast
(MEF) feeders to identify PSC-specific cytotoxic small molecules.
The PSC-MEF co-culture system comprises 2 morphologically
distinct cell types, spindle-shaped MEF feeders which are a mixed
population of differentiated cells and colony forming hESCs with a
high nucleus to cytoplasm ratio representing healthy undifferen-
tiated PSCs. These differences in morphology as well as the unique
arrangement of these 2 distinct cell types (MEFs surrounding
distinct hESC colonies) in the co-culture monolayer helps facilitate
the visual identification of compounds which may be specifically
cytotoxic to hESCs. A ‘‘hollowing-out’’ effect of the co-culture
would be indicative of differential cytotoxicity (Fig. 1a–d).
Briefly, all BGO1V-MEF co-cultures were treated with 10 mM
final concentration of compounds for 12 hours after which visual
inspection of each well was performed under a stereomicroscope to
identify small molecules that were cytotoxic to BGO1V but which
would leave the MEFs intact.
From the screens, 3 structurally related compounds (JC010,
JC011, JC017) from an in-house synthesized compound library
that displayed differential cytotoxicity towards PSCs were identi-
fied (Fig. 2a). Cell viability analysis was performed using the
Resazurin dye, confirmed via Trypan Blue staining (Fig. 1e, f) and
Propidium Iodide DNA content analysis (Fig. 1j, k). Dose response
relationships for each of these 3 active hits were generated using
feeder-free cultures for 3 PSC lines (BGO1V, H9 and iPS-foreskin-
1) (Fig. 2b). PSC-specific cytotoxic effects for these 3 compounds
were found to be consistent across all 3 PSC lines we evaluated.
Overall, JC011 was found to be the most potent, 12 hr treatment
with 10 mM of JC011 resulted in over 99% cell death of BGO1V
cells in feeder-free culture (Fig. 2a). Conversely, cell viability
figures for MRC-5 normal human fibroblasts treated with JC011
at concentrations of up to 100 mM remained very high at over
97% in all cases (Fig. 2b). Average IC50 value for the 3 PSC lines
tested was approximately 20 mM (Fig. 2a). JC011 was also
cytotoxic to the NCCIT embryonic carcinoma line with an IC50
value of approximately 30 mM.
A time-course experiment to assess how quickly JC011 would
induce cell death in the 3 PSC lines used in this study indicated
that maximum cell death of about ,96% would be attainable
following a 36 hr incubation with 20 mM JC011 (Figure S5 in File
S1).
To confirm its specificity for PSCs, we obtained dose response
relationships for JC011 across 4 normal human primary special-
ized cells types ie. MRC-5 fibroblasts, primary human astrocytes
(Lonza), primary human neurons (Neuromics) and primary human
neonatal cardiomyocytes (National Heart Centre, Singapore). Low
cytotoxicity (,5% cell death) towards MRC-5, primary cardio-
myocytes and primary astrocytes were observed for JC011
concentrations of up to 100 mM (Figure S2 in File S1). Primary
human neurons were found to be substantially more sensitive to
JC011 treatment with cell vitality affected at concentrations of
60 mM (Fig. 2b). We further tested JC011 at the IC50 concentra-
tion of 20 mM on several other human cell lines (HepG2, HeLa,
WI-38 and normal human keratinocytes) and found that resultant
cell viability as determined by Resazurin analysis remained high at
.97.5% (Figure S6 in File S1). Additionally, all PSC lines used in
this report were .92% positive for both Tra-1-60 and SSEA-4 as
established by FACS thus confirming specificity of JC011 towards
PSCs (Figure S7 in File S1).
JC011 was also tested on differentiating BGO1V/hOG cultures
harbouring the hOct4::GFP construct. BGO1V-GFP cultures
were induced to differentiate by bFGF starvation; differentiating
cultures were treated at 4-day intervals with 20 mM of JC011 and
cell viability determined via Resazurin analysis. A clear trend was
observable in differentiating BGO1V/hOG cultures that were
treated with JC011. Decreasing GFP levels indicative of increasing
PSC differentiation were contemporaneous with an overall
increase in cell viability, thus confirming specificity of JC011 for
the undifferentiated PSC phenotype (Fig. 2c).
Structure-activity relationship studies on the active hits were
carried out to determine the functional groups that are responsible
for eliciting the activity and also to optimise the potency of these
molecules. A focused library of analogues with different substit-
uents at the aromatic ring, linker and varying lengths of alkyl side-
chains were screened (Fig. 3). Our studies show that it is crucial to
have 2 hydroxyl groups present at the carbon-3 and -4 positions on
the aromatic ring. As shown by the data of JC005 and JC007,
replacement of any of these hydroxyl groups with a methoxy
(CH3O-) group led to a significant drop of cytotoxicity towards
PSCs and specialised cells (Fig. 2d).
The activity can also be affected by varying the length of the
alkyl side chains. JC040, with a 9-carbon side chain, has an IC50
value of approximately 16 mM (Fig. 2d) and it is slightly more
potent than JC011. However, extending the alkyl side chain to 10
carbons (JC049) and longer (JC048, JC050) generally decreased
the potency. This could be attributed to an increase in lipophilicity
which decreases their aqueous solubility. Even though JC040
showed a higher potency, JC011 was selected as our model
compound for further screens as it has a better solubility profile.
The nature of the linker between the alkyl side chain and the
aromatic core was also investigated. It was shown that JC011
which has an amide linkage is more potent, as compared to JC010
which has a urea (-NHCONH-) linkage.
To establish if treatment of hESCs with JC011 would abolish
teratoma formation in vivo, we treated 16106 BGO1V cells with
20 mM JC011 for 12 hrs prior to injecting the treated cells into the
thigh muscle of SCID mice. JC011-treated hESCs failed to form
teratomas in all SCID mice while untreated controls readily
formed teratomas (Fig. 4). To better simulate the efficacy of a
JC011-based enrichment strategy as part of a differentiation
protocol, heterogeneous populations of BGO1V and primary
neonatal cardiomyocytes or astrocytes were mixed in pre-
determined ratios (10:90, 20:80, 30:70, 60:40 and 50:50). The
mixed cultures were seeded, allowed to adhere for 14 hrs and
subsequently treated with JC011 at 20 mM for both BGO1V-
cardiomyocyte cultures and BGO1V-astrocyte cultures for 12 hrs
after which cultures were analysed by FACS for SSEA-4 and
TRA-1-60 expression to determine enrichment percentages. Up to
6-fold enrichment for differentiated cardiomyocytes and astrocytes
were obtained from the different mixed cell populations following
JC011 treatment without adversely affecting cell vitality (Fig. 4e).
These results are an improvement over the 4.5-fold enrichment
figures obtained by single antibody sorting using the classical
hESC SSEA-4 or TRA-1-60 antibodies [14]. No further increase
in cardiomyocyte cell death beyond 5% was observed following
prolonged exposure (up to 5 days) to 20 mM JC011 (Fig. 4f).
To better understand the toxicity of JC011 in vivo and in a whole
animal model, acute toxicity (LC50) for JC011 was determined in
zebrafish. The results suggest that JC011 was toxic to zebrafish
embryos only at very high concentrations (JC011
LC50 = 398.9 mM) (Figure S3 in File S1). JC011 LC50 values for
zebrafish embryos are comparable in magnitude to the reported
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values for several FDA approved drugs such as Gentamycin
Sulfate (440 mM) and Verapamil Hydrochloride (170 mM) [21].
In order to further assess developmental toxicity of JC011, its
maximum non-lethal concentration (MNLC) was determined by
exposing developing zebrafish to JC011 from the early gastrula
stage at 6 hours post fertilization(hpf)to 5 days post fertilization
(dpf). MNLC for JC011 was determined at approximately
425 mM. Zebrafish were treated at MNLC from 6 hpf to 5 dpf
and visually assessed using a stereomicroscope. At 425 mM
(MNLC), 21.1% (4/19) malformations were observed. Zebrafish
treated with JC011 exhibited accidental incidences of trunk/tail/
notochord, liver and intestine malformation, but these figures were
not statistically significant (p.0.05) (Figure S3 in File S1). These
data confirm that JC011 is not developmentally toxic to
developing zebrafish embryos from the gastrula stage onwards
and support the finding that JC011 toxicity is confined to very
early embryonic cells.
Comparative gene expression profile analysis with microarray
was next performed to elucidate the mechanisms of JC011-
mediated PSC cytotoxicity. Total RNA from JC011-treated
BGO1V cultures was extracted at 6 hr and 12 hr time-points
and used for gene expression analysis while total RNA from
untreated BGO1V cultures served as controls. We found rapid
upregulation of genes associated with the unfolded protein
Figure 1. Morphology of BGO1V-MEF cultures following treatment with 20 mM JC011 for 12 hrs. ‘‘Hollowing-out’’ effect in BGO1V-MEF
cultures, feeders remain intact and viable (A–D). Trypan blue staining of untreated control BGO1V single cells (E). Trypan blue staining of JC011
treated BGO1V single cells showing an increase in Trypan blue uptake (F). Propidium Iodide DNA content analysis of control untreated BGO1V cells
(G). Propidium Iodide DNA content analysis of JC011 treated BGO1V after 6 hrs showing a rapid increase in the sub-G1 fraction (H). R1 = sub-G1
fraction, R2 =G1 fraction, R3 = early/late S-phase fraction, R4 =G2/M fraction.
doi:10.1371/journal.pone.0085039.g001
Figure 2. Dose response cytotoxicity data. Dose response curves for 3 PSC cell lines (BGO1V, H9 and iPS-Foreskin-1) following treatment with
JC011 (A). Dose response curves for 3 specialized somatic cell lines (MRC-5, human primary neurons and human neonatal cardiomyocytes) treated
with JC011 (B). Time course cytotoxicity analysis for differentiating BGO1V cultures treated with JC011 at 4-day intervals following bFGF withdrawal
(C). Dose response curves for 3 JC011 analogues (JC005, JC017 and JC040) showing that JC040 with a longer alkyl side-chain is the most potent
analogue (D). Cell viability values were normalized to untreated controls and reported as mean 6 S.D. of three independent experiments (n = 3).
doi:10.1371/journal.pone.0085039.g002
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response (UPR) also known as the endoplasmic reticulum stress
response (ER stress) in 6 hr and 12 hr JC011-treated cultures.
More than 10 ER stress related genes were found to be present in
the top 50 upregulated list of genes (Fig. 5).
The ER stress response, also known as the unfolded protein
response (UPR), is a cellular stress mechanism activated in
response to an accumulation of mis-folded proteins in the lumen
of the endoplasmic reticulum [22,23]. In conditions of prolonged
stress, UPR commits the cell to a pathway of apoptosis. Signalling
intermediates downstream of all 3 main UPR receptor pathways
have been identified as having pro-apoptotic roles [22,23]. The 3
principal UPR receptors involved in the UPR apoptosis cascade
are Ire1, ATF6 and PERK. Microarray analysis further revealed
that the downstream components and genes of the PERK/ATF4/
DDIT3 pathway in particular were specifically upregulated in
JC011-treated BGO1V cells. DDIT3 (also known as CHOP),
CHAC1, ATF3 and ATF4 are key mediators of PERK mediated
UPR apoptosis; all 4 of these genes were found to be very highly
upregulated and this was confirmed by qRT-PCR (Fig. 5).
Moreover, microarray data also indicated fluctuations in
oxidative stress and calcium signalling in JC011-treated BGO1V
cells. GCLM and GSR, 2 genes involved in Glutathione
metabolism were found to be rapidly upregulated following
JC011 treatment. Changes in intracellular ROS levels following
JC011 treatment were examined with the fluorescent ROS
sensitive dye DCHF-DA. Unexpectedly, ROS levels in DCHF-
DA cells were found to be rapidly reduced following JC011
treatment in BGO1V cells after a short incubation period of 3 hrs.
In contrast, ROS levels in BGO1V cells were not reduced
following treatment with the non-cytotoxic JC005 and JC007
analogues although both JC011 and JC005 share similar
antioxidant profiles as determined by the Oxygen Radical
Figure 3. Table of structure, molecular mass, ORAC and DPPH antioxidant data for 6 JC analogues (JC005, JC007, JC010, JC011,
JC017 and JC040).
doi:10.1371/journal.pone.0085039.g003
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Absorbance Capacity (ORAC) and Di(phenyl)-(2,4,6-trinitrophe-
nyl)iminoazanium (DPPH) antioxidant assays (Fig. 6 & Fig. 3).
Instead, ROS levels were increased following JC005 treatment but
this increase was not associated with any observable cell death.
Next, pharmacological intervention with a well-studied ER
stress inducer dithiothreitol (DTT) was performed to determine if
JC011 mediated PSC cytotoxicity was a specific outcome of JC011
treatment or a more general non-specific outcome which could be
replicated by any UPR/ER stress inducer. Treatment with DTT,
which causes disulphide bond disruption in ER proteins, did not
result in any observable increase in BGO1V cell death when
compared to untreated controls. PSC-specific cytotoxicity in
BGO1V cells could not be replicated with DTT treatments
confirming that JC molecule mediated PSC-specific cytotoxicity is
a property specific to the JC molecule series (Figure S8 in File S1).
We then performed siRNA knockdown on 2 genes, DDIT3 and
ATF4 to confirm the involvement of PERK/ATF4/DDIT3 ER
stress pathway in JC011 mediated PSC-specific cytotoxicity.
siRNA knockdown was carried out in NCCIT cells for maximum
transfection efficiency and confirmation of transcript knockdown
was determined by qRT-PCR. Briefly, NCCIT cells were allowed
to recover for a period of 24 hrs following siRNA knockdown and
treated with JC011. Cell viability analysis indicated that ATF4
knockdown successfully attenuated JC011 cytotoxicity in NCCIT
cells (P,0.05) thereby confirming the role of PERK/ATF4/
DDIT3 ER stress in JC011 induced PSC cytotoxicity. DDIT3
knockdown NCCIT cells also showed a similar attenuated
cytotoxic response when challenged with JC011 but these data
were not statistically significant (Fig. 7). This result could perhaps
be due to other components of PERK/ATF4/DDIT3 ER stress
pathway which may potentially substitute for loss of DDIT3
activity. ROS levels determined by DCHF-DA FACS were used as
surrogate readout to confirm knockdown of ATF4 and DDIT3.
ATF4 knockdown resulted in a recovery of ROS levels compa-
rable to untreated controls while DDIT3 knockdown resulted in
no significant ROS recovery (Figure S9 in File S1)
Discussion
Considerable progress has been achieved in establishing
optimum conditions to propagate and differentiate PSCs into a
variety of lineages of functional specialized cells for human cell
replacement therapies. These advancements are further under-
scored by recent U. S Food and Drug Administration approval of
clinic trials to use PSC-derived cells to treat spinal cord injury and
macular degeneration [24,25]. Nonetheless, the teratoma risk
associated with contaminating PSCs in differentiated cell popula-
tions still remains. This problem is further aggravated by the
intrinsic propensity for some PSC derivatives to undergo
dedifferentiation in situ [4,11]. Even if ensuing data from clinical
trials supports the efficacy and safety of the PSC-based therapies,
the teratoma risk might have to be continuously monitored when
PSC-based therapies are routinely applied in a clinical setting.
Antibody-based solutions to remove undifferentiated PSCs in
vitro are currently popular. The high specificity of an antibody
towards a particular antigen also has its drawbacks as any
antibody-based strategy could in theory be limited by the
specificity of the expression of its associated surface antigen. It is
well documented that PSC cultures comprise of a mixed
population of cells with slightly different phenotypes [3]. Conse-
quently, the undifferentiated cells from one sample may not
express similar groups of surface antigens; this would necessitate
the use of multiple combinations of antibodies for any antibody-
based enrichment strategy. In addition, Fluorescence Activated
Cell Sorting (FACS) or Magnetic Activated Cell Sorting (MACS)
based enrichment protocols require single-cell suspensions. Ma-
nipulation of single cells may not be appropriate in all tissue
engineering scenarios especially when complex 2-D or 3-D multi-
layer cell constructs are the final product for transplantation.
It is also difficult to envisage the use of an antibody as a
preventive drug in an established clinical transplantation regime
where patients may require administration of a drug for a period
of time following the transplantation procedure to prevent
teratoma formation. Small molecules which are specifically
cytotoxic to PSCs and non-toxic to normal specialized cells could
be a better solution in these scenarios. Small molecules are cheaper
and easier to synthesize. They also show favourable pharmaco-
kinetic profiles and elaborate FACS or MACS set-ups and
protocols are also not required.
While this manuscript was in preparation, a high throughput
screen study of over 50,000 small molecules reported the
identification of 15 pluripotent cell-specific inhibitors (PluriSIns)
[26]. Interestingly, Ben-David et al determined that their most
selective PluriSIn induces ER stress apoptosis in PSCs [26]; we
corroborate these findings in identifying the ER stress pathway as
a new target for understanding the signalling cascades which
govern apoptosis in PSCs.
However, in contrast to the PluriSIns described in the study by
Ben-David et al, our compounds (JC011, JC010, JC017 and
JC040) may not be involved in lipid metabolism as our molecules
are structurally different and do not share a phenyl-hydrazine
moiety which is a common feature of 9 PluriSIns [26]. Instead, the
4 JC compounds we describe have high ORAC and DPPH values
indicative of strong anti-oxidant properties (Fig. 3). We also
establish that JC molecule PSC cytotoxicity is mediated mainly
through the PERK/ATF4/DDIT3 signalling arm of the ER stress
pathway and concomitant with a small but rapid reduction of
intracellular ROS levels. This latter observation is unexpected
because cell death as a result of the ER stress response is more
commonly associated with an increase rather than a decrease in
endogenous intracellular ROS levels [22,23].
We present in this report a group of novel small organic
molecules that are cytotoxic and effective against PSCs. These
molecules can be easily and efficiently synthesized besides having
several advantages over existing antibody-based enrichment
strategies for the removal of PSCs from their differentiated
progenies. These molecules should also be useful as an in vitro tool
to help enrich certain differentiated PSC derivatives by eradicating
contaminating undifferentiated PSCs. Although toxicity towards
primary cardiomyocytes (,5–9%) was observed following treat-
ment with JC011 (20–100 mM) and toxicity towards astrocytes
(,5%) observed at 20 mM, this should be acceptable as JC011
concentrations of ,20 mM were found to be sufficient in reducing
Figure 4. JC011 treated PSCs fail to form teratomas in SCID mice and can be effectively used to enrich for specialized cells. Teratoma
sections from SCID mice. Controls showing typical teratoma tissue organization representative of all 3 germ layers, A = Cartilage, B =Gut/Intestine, C,
D = JC11 treated sample showing plain muscle tissue with no teratoma growth (A–D). BGO1V and primary neonatal cardiomyocytes were mixed and
seeded in pre-determined ratios (10:90, 20:80, 30:70, 60:40 and 50:50). The mixed cultures were treated with JC011 at 20 mM for 12 hrs followed by
SSEA-4 and TRA-1-60 FACS analysis to determine enrichment ratios (E). Time course cell viability data for JC011 (20 mM) treated primary neonatal
cardiomyocytes indicate that cardiomyocytes maintain high cell viability (.95%) even after a 5-day incubation period with JC011 (F).
doi:10.1371/journal.pone.0085039.g004
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PSC contamination in differentiated cell populations by up to 6-
fold (Fig. 4e). Additionally, prolonged exposure of cardiomyocytes
to JC011 (20 mM) for up to 5 days resulted in no further increase
in cell death. These statistics are an improvement over the 4.5-fold
enrichment figures obtained by single antibody sorting using
classical hESC antibodies [14]. Primary neurons however were
found to be significantly affected by JC011 at 20 mM; this finding
Figure 5. Comparative microarray analysis reveals involvement of the PERK/ATF4/DDIT3 ER stress pathways. Clustering of key
differentially upregulated ER stress genes in BGO1V following 6 hr and 12 hr treatments with 20 mM JC011 (A). Top 10 components of the PERK/
ATF4/DDIT3 ER stress pathway that were found to be rapidly upregulated in JC011 treated BGO1V cells (B). qRT-PCR confirmation of upregulated
UPR/ER stress pathway genes following JC011 treatment (C).
doi:10.1371/journal.pone.0085039.g005
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could severely limit the use of the JC compounds in neuronal
differentiation strategies.
Furthermore, we corroborate the findings of Ben-David et al
[26] in identifying the ER stress pathway as a new target for
understanding the signalling cascades which govern apoptosis in
PSCs. A deeper understanding of the PSC apoptosis machinery
will provide an effective means to eliminate teratoma-forming cells
from cell preparations with clinically desirable phenotypes,
triggering selective apoptosis in PSCs could potentially be one
solution to eliminate unwanted teratoma-forming cells. Although
additional safety studies have to be performed, our findings
indicate that the molecules we describe may perhaps have the
potential to be used safely in vivo. Downstream, together with other
enrichment methods such as antibody-based sorting, these
molecules could perhaps function as part of a strategy to safeguard
against teratoma formation in PSC-based cell replacement
regimes.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations of the Responsible Care and Use of Laboratory
Animals guide of the National University of Singapore and
Nanyang Polytechnic. All animal work was conducted according
to relevant Singapore and international NACLAR guidelines at
the ASTAR Biological Resource Centre, Singapore. The animal
experimentation protocol was approved by the Institutional
Animal Care and Use Committee of the National University of
Singapore (IACUC Permit No 090446). All surgery was per-
formed under sodium pentobarbital/ketamine mix anesthesia and
all efforts were made to minimize suffering. Only commercially
available pluripotent stem cell lines were used in this research.
Approval for pluripotent stem cell research was obtained from the
National University of Singapore Institutional Review Board
(NUS-IRB Review Permit No 09-301).
Cell Culture Protocols
All PSC lines were cultured in Dulbecco’s modified Eagle’s
medium/Ham’s F-12 medium containing GlutaMax supplement-
ed with 20% serum replacement, 1 mM sodium pyruvate,
0.1 mM nonessential amino acids, (all from Life Technologies),
0.1 mM b-mercaptoethanol (Sigma), and 8 ng/ml basic fibroblast
growth factor (Chemicon). PSCs were grown on primary mouse
embryonic fibroblasts (MEFs) obtained from E12.5 d.p.c. 129sv
mice. Colonies were serially passaged in ‘‘bulk culture’’ format
using Collagenase IV (Life Technologies) and moved to feeder-free
culture in mTeSRTM medium (Stem Cell Technologies) when
required. PSC lines between passages 30 and 35 were used in this
study. HepG2, HeLa, WI-38, Human Keratinocytes, MRC-5 and
NCCIT cells were cultured as recommended by American Type
Culture Collection (ATCC). Primary hN2TM Human Neurons
(Neuromics) were grown in hN2TM human neuron culture media
(Neuromics). Primary human neonatal cardiomyocytes (Celpro-
gen) were grown D10 media. Primary human astrocytes (Lonza)
were cultured in specialized human astrocyte media (Lonza).
FACS and Propidium Iodide DNA Content Analysis
Cells were washed with PBS followed by fixation with ice-cold
70% ETOH for 5 min. Fixed cells were washed with PBS twice
and resuspended in 300 ml Propidium Iodide solution (69 mM
Propidium Iodide, in 38 mM NaCitrate from Sigma). 20 ml of
10 mg/ml RNase was added to remove interfering RNA.
Following incubation at 37uC for 45 min, DNA content was
determined via FACS analysis using a Beckman Coulter Cell Lab
Quanta SC. SSEA-4 and TRA-1-60 antibodies used for FACS
were obtained from Chemicon. All experiments were performed in
triplicate.
Trypan Blue Cell Viability Analysis
Cell suspensions were diluted 1:1 with 10 ml 0.4% w/v Trypan
Blue Solution, incubated for 10 min at room temperature and
observed under 206 phase optics in a hemocytometer for cell
counting.
ResazurinTM Cell Viability Analysis
Cells were seeded in 96 well multi-well dish format at a density
of 10,000 cells per well. Cells were washed with PBS before
ResazurinTM (Sigma) solution (40 mg/ml final concentration) was
added to each well. Following an incubation period of 2 hrs at
37uC before fluorescence readouts were obtained a TecanTM plate
reader (Emission wavelength: 590 nm, Excitation wavelength:
535 nm, Gain= 25). All experiments were performed in quadru-
plicate.
Total RNA Isolation and First-Strand cDNA Synthesis
Total RNA was extracted using TRIZOL (Life Technologies)
and reverse transcribed using the SuperScript IITM first-strand
synthesis system (Life Technologies). Total RNA was quantified
using a ND-1000 spectrophotometer (NanoDrop Technologies,
Rockland, DE, USA) and contaminating genomic DNA removed
with DNA-freeTM reagent (Life Technologies) before reverse
transcription.
qRT-PCR
Real-time quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR) analysis was conducted using the ABI
PRISM 7500 Fast Sequence Detection System using Predesigned
Assays on Demand TaqManTM probes and primer pairs obtained
from Life Technologies. After an initial incubation step for
2 minutes at 50uC and denaturation for 10 minutes at 95uC,
qRT-PCR was carried out using 40 cycles of PCR (95uC for
15 seconds, 60uC for 60 seconds). Equal amounts of input first
strand cDNA were used for all qRT-PCR reactions, reactions
were performed in quadruplicate, and GAPDH RNA levels served
as internal controls. Changes in gene expression levels were
calculated using the 2ddCT method. Student’s T-test statistic was
used to analyze qRT-PCR data.
Microarray
hESCS used for the microarray experiment were grown feeder-
free and were .95% positive for the Tra-1-60 marker. Cell
viability analysis with Resazurin prior to treatment with JC011
showed all cells to be .98.5% viable. RNA was extracted using
Figure 6. JC011 and JC040 reduce ROS levels in PSCs. Cytotoxic JC011 and JC040 induce a small but rapid reduction of intracellular ROS levels
in BGO1V cells as confirmed by DCHF-DA FACS analysis 3 hrs after treatment (A). JC007 (non-cytotoxic) does not alter endogenous ROS levels while
JC005 (non-cytotoxic) increases ROS levels but without any corresponding cytotoxicity to BGO1V (B). FACS histograms are representative outcomes
of 4 independent experiments. DCHF-DA stained JC011 treated BGO1V cells (C, D). DCHF-DA stained JC005 treated BGO1V cells (E, F).
doi:10.1371/journal.pone.0085039.g006
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standard TrizolTM protocol and subjected to spectrophotometric
measurement (BioSPEC-Mini, Shimadzu) and quality determined
using an Agilent Bioanalyzer. All samples show OD260/OD280
ratios of between 1.78–2.02 with concentrations ranging from
,600 ng/mL to ,980 ng/mL. Results from an Agilent Bioanaly-
zer analysis showed that all the samples had the RIN (RNA
Figure 7. siRNA knockdown of the key ER stress genes ATF-4 and DDIT3 leads to reduced sensitivity towards JC011 in NCCIT cells.
ATF-4 and DDIT3 were silenced via siRNA knockdown. Sensitivity towards JC011 was attenuated in DDIT3 knockdown and ATF-4 knockdown
(P,0.05) NCCIT cells thereby confirming involvement of the PERK/ATF4/DDIT3 ER stress pathway in JC011 mediated cytotoxicity (A–E). qRT-PCR
confirmation of ATF-4 and DDIT3 transcript knockdown (F). Cell viability figures were normalized to untreated controls and reported as mean 6 S.D.
of three independent experiments (n = 3). Statistical analysis was performed with the Student’s T-test.
doi:10.1371/journal.pone.0085039.g007
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integrity Number) of 7.5 to 9.5. The AgilentTM two-colour
microarrays were used for comparative microarray analysis.
cRNA was prepared according to the manufacturer’s recom-
mended protocol (AgilentTM Two-Color Microarray-Based Gene
Expression Analysis, Quick Amp Labeling v5.7). Normalization
and data analysis was done using GeneSpring GX version 10.0
and Microsoft Excel. All experiments were performed in triplicate
(N= 3). A gene was considered differentially expressed if fold-
difference relative to controls was $3.
DCHF-DA ROS Detection, ER Stress Induction and N-
acetyl cysteine treatment
DCHF-DA solution was used at a final working concentration
of 10 mM. Adherent cells in PBS solution were incubated 5 min
room temp with DCHF-DA after which cells were visualized
under fluorescence microscope with FITC filters. Bright green
fluorescing cells were indicative of cells with high ROS content.
To induce non-specific ER stress, DTT (Sigma) was added at a
final concentration of 3 mM. All experiments were performed in
triplicate. All DCHF-DA experiments were performed after a 3 hr
incubation period with JC011. Cells were treated with ROS
scavenger N-acetyl cysteine (Sigma) at a final concentration of
100 mM.
Teratoma Formation in SCID mice
Approximately 1 million stem cells were injected intramuscu-
larly into the right hind leg of a 10-week-old male SCID-beige
mouse. 5 mice were used for each experimental arm including
controls. Mice were monitored 2–3 times/week for a period of 15
weeks and the size of the teratomas recorded weekly. Histological
evaluation of paraffin embedded teratoma sections was performed
with H&E staining by a trained pathologist. All animal experi-
ments were carried out in strict accordance with the recommen-
dations of the Responsible Care and Use of Laboratory Animals
guide of the National University of Singapore and Nanyang
Polytechnic.
Zebrafish Acute Toxicity Determination
Dechorionated wild-type AB strain zebrafish were distributed
into 12-well plates in 3 ml fresh fish water. To determine LC50,
zebrafish were treated from 2 dpf to 5 dpf. Ten concentrations:
0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 and 500 mM were assessed to
estimate LC50. Dead zebrafish were counted and removed daily.
At the end of treatment, total number of dead animals was used to
generate a lethality curve by plotting % lethality vs concentration.
Based on lethality curves, LC50s were estimated through logistic
regression with the JMP8 software. Experiments were performed 3
times to obtain mean and SD of LC50. Detailed protocols are
provided in the File S1. All zebrafish acute toxicity assays were
performed by a contract service provider, GenScript Pte Ltd.
Zebrafish Teratogenicity Determination
Chorionated wild-type AB strain zebrafish were distributed into
6-well plates in 3 ml fresh fish water. To determine developmental
toxicity, zebrafish were treated at MNLC from 6 hpf (Gastrula
stage) to 5 dpf. Zebrafish treated with 0.1 mM 9-cis retinoic acid
served as positive control and 0.1% DMSO as vehicle control.
Untreated zebrafish were used to demonstrate vehicle (0.1%
DMSO) did not have adverse effect on zebrafish. At the end of
treatment, zebrafish were visually assessed using a dissecting
microscope for malformations. A zebrafish exhibiting defects in
any end point was considered abnormal and % abnormal animal
for each compound was determined using the following formula:
% abnormal zebrafish = (number of abnormal zebrafish/
20)6100%. The number of zebrafish exhibiting at MNLC was
counted and compared with vehicle control. Fisher’s exact test was
used to analyze the data; a compound was considered teratogenic
when significant difference (p,0.05) was observed in compound
treated zebrafish. Detailed protocols are provided in supplemen-
tary material. All zebrafish developmental toxicity assays were
performed by a contract service provider, GenScript Pte Ltd.
siRNA Transfection
Cells were seeded in 24-well plates 48 hours before siRNA
transfection in order to have 60–70% confluency on the day of
transfection. Cells were transfected with siRNA (Dharmacon)
targeting (ATF4 and DDIT3) and control siRNA at a final
concentration of 100 nM using DharmaFECT 2 reagent (Dhar-
macon). ON-TARGET plus siRNA pool (Dharmacon) was used
for all knockdown experiments because it contains a pool of four
individual siRNA sequences for the target gene. RNA knockdown
was confirmed by assessing mRNA levels with qRT-PCR.
Preparative HPLC Protocol
Preparative HPLC was performed on a Shimadzu LC-8A
HPLC system equipped with a CBM-20A PDA detector, Gilson
215 liquid handler and fraction collector using a X-Bridge Prep
C18 (30 mm I.D.650 mm, 5 m) column. An isocratic elution with
20% CH3CN, 80% (0.1% formic acid/H2O) at a flow rate of
20.0 mL/min for 5 min was used. This was followed by a gradient
elution starting with 20% CH3CN, 80% (0.1% formic acid/H2O),
and ending with 100% CH3CN at a flow
Liquid Chromatography-Mass Spectrometry (LC-MS)
LC-MS data of JC005, JC007, JC010, JC011, JC017 and
JC040 were collected on a Shimadzu LCMS-IT-TOF instrument
equipped with SPD-M20A PDA detector, LCMS-IT-TOF MS
detector and LC-20AD binary gradient pump using a Shimpack
VP-ODS (2.0 mm I.D.6150 mm) column (File S1). An isocratic
elution with 20% H2O and 80% CH3CN at a flow rate of
0.2 mL/min over 3 min was used.
Nuclear Magnetic Resonance (NMR) Spectroscopy
1H and 13C NMR spectra of JC010, JC011 and JC040 were
recorded on a Bruker AVANCE-400 NMR spectrometer (File S1).
The compounds were dissolved in CD3OD.
Synthetic Procedure for Analogues JC005, JC011, JC040,
JC048-050
To a solution of the hydrochloride or hydrobromide salt of an
amine (1 mmol) in anhydrous N,N-dimethylformamide (DMF)
(2 mL) was added N,N-diisopropylethylamine (DIPEA) (2 mmol)
to liberate the amine. After stirring at room temperature for
10 min, nonanoyl chloride (1 mmol) was added. The solution was
stirred at room temperature for 6 to 24 h. After the reaction, water
(40 mL) was added to the solution. The reaction mixture was
transferred to a separating funnel and extracted with dichloro-
methane, CH2Cl2 (366 mL). The organic extracts were concen-
trated under reduced pressure to give a crude product. The crude
product was then purified by silica gel column chromatography
(using hexane/ethyl acetate, 2:1 v/v, as eluent) or preparative
HPLC (using the protocol set out above) to give the final product
(Figure S10 in File S1).
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Synthetic Procedure for Analogues JC007, JC010 and
JC017
To a solution of the hydrochloride or hydrobromide salt of an
amine (1–2 mmol) in anhydrous dichloromethane, tetrahydrofu-
ran or N,N-dimethylformamide (DMF) (2–4 mL) was added N,N-
diisopropylethylamine (DIPEA) (1–2 mmol) to liberate the amine.
After stirring at room temperature for 10 min, isocyanate (1–
2 mmol) was added. The solution was stirred at room temperature
for 6 to 24 h. After the reaction, water (20 mL) was added to the
solution. The reaction mixture was transferred to a separating
funnel and extracted with dichloromethane, CH2Cl2 (3610 mL).
The organic extracts were concentrated under reduced pressure to
give a crude product, which was purified by silica gel column
chromatography (using hexane/ethyl acetate, 2:1 v/v, as eluent) or
preparative HPLC (using the protocol set out above) to give the
final product (Figure S11 in File S1)..
Supporting Information
File S1 Figures S1–S11. Figure S1 in File S1: Table of LC-MS
data for JC analogues. Figure S2 in File S1: NMR spectra for JC
analogues. Figure S3 in File S1: Zebrafish acute toxicity and
developmental study data. Figure S4 in File S1: Normal human
astrocytes (Lonza) were treated with JC005, JC010, JC011 and
JC017 at 20 mM final concentration for 12 hrs following which the
Resazurin assay was used to determine cell viability. Cell death
values are normalized to untreated controls and reported as mean
6 S.D. of three independent experiments (n = 3). Figure S5 in File
S1: Time-course cell viability study to determine kinetics of JC011
mediated cell death in 3 PSC lines. Maximum cell death of
approximately 96% is attained for both BGO1V and H9 following
a 36 hr incubation with 20 mM JC011. Cell death values are
normalized to untreated controls and reported as mean 6 S.D. of
three independent experiments (n = 3). Figure S6 in File S1: Cell
viability analysis for JC011 (20 mM, 12 hrs) treated HepG2, HeLa,
WI-38 and normal human keratinocytes. Resultant cell viability as
determined by Resazurin analysis remained high at .97.5% for
all cell lines. Cell death values are normalized to untreated controls
and reported as mean 6 S.D. of three independent experiments
(n = 3). Figure S7 in File S1: Tra-1-60 and SSEA-4 immunomar-
ker FACS analysis for BGO1V, H9 and iPSC-foreskin-1. All PSC
lines were.95% positive for both Tra-1-60 and SSEA-4 stem cell-
specific antigens (n = 3). Figure S8 in File S1: Non-specific ER
stress inducer DTT does not induce cell death in BGO1V. PSC-
cytotoxicity in BGO1V cells could not be replicated with DTT
treatment confirming that JC011 mediated PSC-cytotoxicity is a
property specific to the JC molecule series. Cell death values are
normalized to untreated controls and reported as mean 6 S.D. of
three independent experiments (n = 3), * = P,0.05. Figure S9 in
File S1: Surrogate ROS levels in NCCIT following ATF4 and
DDIT3 siRNA knockdown. ATF4 knockdown resulted in a
recovery of ROS levels in JC011 (20 mM) treated NCCIT cells
comparable to untreated controls. DDIT3 knockdown resulted in
no significant recovery in ROS levels (n = 3). Figure S10 in File S1:
Synthetic Procedure for Analogues JC005, JC011, JC040, JC048-
050. Figure S11 in File S1: Synthetic Procedure for Analogues
JC007, JC010 and JC017.
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